No approved treatment has been able to halt the underlying disease processes in the brain in AD patients, and no new treatment has been approved at all in the last decade in this field.Research, and the development of new therapies, has been fraught by a large number of late-stage, high-profile failures in recent years and a vast number of asset suspensions in the earlier stages of development, too.
According to data held by BioMedTracker (BMT), the AD pipeline in the US includes 47 Phase I products that have been suspended or placed on a program hold. Of these 47 drugs, AD was the lead indication for 24 of them
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?